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Strongyloidiasis remains an underesti-
mated public health problem, just as it was
at the dawn of last century.
In 1901, Professor William Sydney
Thayer published a review, ‘‘On the
Occurrence of Strongyloides intestinalis in
the United States,’’ concluding: ‘‘…one
may be justified in emphasizing the
following points:
1. ‘‘Diarrhoea associated with the pres-
ence of Strongyloides intestinalis occurs in
the United States.
2. ‘‘The observation, in the Johns Hop-
kins Hospital, of three cases within
three years, […] suggests that this
parasite may be more frequent than
hitherto been supposed.
3. […]
4. […]
5. ‘‘More systematic examinations of the
faeces both in public clinics and in
private practice are much to be de-
sired.’’ [1]
More than one century later, the key
issues regarding this parasite (subsequently
renamed Strongyloides stercoralis) are essen-
tially the same, and although researchers
have recently given more attention to this
infection, systematic action plans still lag
behind. There is widespread agreement in
the scientific community that its preva-
lence is largely underestimated [2]. The
current estimate of 30 to 100 million
infected persons in the world dates back to
review articles published between 1989
and 1996 [3,4], and is cited by most
subsequent papers. These figures were
mostly based on surveys aimed at defining
the prevalence of parasitic infections,
without using adequate diagnostic tech-
niques for S. stercoralis. For example, Kato-
Katz, a technique that is commonly used
in surveys aiming to assess intestinal
helminth infections [5], is poorly sensitive
for this parasite. Larvae of S. stercoralis in
stool are often scanty, and therefore they
are most often missed by this technique
that examines a small amount of faeces
(between 20 and 50 mg, depending on the
template). Larvae can be detected by this
technique only occasionally, when the
larval output is particularly high [6]. More
reliable prevalence estimates have been
made by geographically confined surveys,
using alternative faecal-based diagnostic
methods that are much more sensitive
such as Baermann or Koga agar plate
culture [7,8]. Serology (ELISA or IFAT) is
even more sensitive, but its specificity is
less well defined. Problems of cross-
reactivity seem to arise especially in areas
where other nematodes, particularly filar-
iae, are also endemic. New and promising
tools such as serologic methods based on
recombinant antigens or PCR are also
available in some referral centers. Howev-
er, the optimal diagnostic strategy, both
for epidemiological surveys and for indi-
vidual diagnosis and screening, has yet to
be defined and certainly deserves further
research [9].
Nevertheless, global prevalence esti-
mates should probably be revised, based
on the studies using diagnostic techniques
that are better suited to S. stercoralis.
If we take hookworm as a comparison, as
they have the same route of infection as S.
stercoralis, we observe that surveys using (for
S. stercoralis) Baermann and/or coproculture
report a ratio of S. stercoralis to hookworm of
1/4 to 1/1 or more [7,10–14]. In a recent
study comparing the Kato-Katz method
and the spontaneous sedimentation in tube
technique (SSTT) for the diagnosis of
intestinal parasites in the Amazonian basin
of Peru [7], the researchers found the same
prevalence with both techniques for hook-
worm (14%) as well as for Ascaris lumbricoides
and Trichuris trichiura (both 5%), while for S.
stercoralis the prevalence was 0% with Kato-
Katz, versus 16% with the alternative
method, and 22% if agar plate culture
was added. The ratio of S. stercoralis to other
helminthes would be even higher if we had
to consider serologic surveys [12,15,16],
and the figures would be different if
multiple sampling were to be used [8]. If
we refer to the current estimate of 740
million people infected with hookworm
globally [17], a prevalence of at least 370
million people infected with S. stercoralis
worldwide seems a more reasonable (and
probably still conservative) figure. Better
tools are needed for a more correct
estimation of S. stercoralis prevalence, using
at least one of the best available diagnostic
methods in stools such as Baermann or
Koga agar plate culture, and adding when
possible an accurate serologic test.
Furthermore, the burden of mortality
and morbidity associated with this parasite
is poorly defined. Going back to 1933, we
read: ‘‘history of the case supports the
considerable accumulated evidence that
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strongyloidiasis may give rise to severe
symptoms’’ [18].
We now know that disseminated stron-
gyloidiasis (Figure 1) is a life-threatening
condition for immunosuppressed patients,
with death often occurring in a few days.
In patients with hematologic malignancies
(especially lymphoma), medically induced
immune suppression (e.g., transplant re-
cipients), or under corticosteroids (some-
times even for the symptoms caused by an
unrecognized infection with S. stercoralis),
the autoinfection cycle of this parasite
becomes overwhelming, with larvae in-
vading virtually all organs and tissues [19].
Nevertheless, the magnitude of this risk is
unclear. How many chronically infected
people receiving steroids, or exposed for
any reason to one of the other well-known
risk factors for severe disease, are likely to
develop dissemination? Most cases have
been reported in western countries or
in other affluent countries where the
prevalence of the infection is low and
about half the cases are seen in migrants
[20]. Even there, severe cases often remain
undiagnosed, as the clinical presentation is
variable and nonspecific. In most of
African, Asian, and Latin American coun-
tries, reports of severe and fatal strongy-
loidiasis are lacking or exceedingly rare,
meaning that most cases must be missed.
Moreover, in some of them HTLV-1
infection, one of the recognized risk factors
for disseminated disease, is relatively
common [21]. Furthermore, in countries
in economic transition, given the increase
in chronic medical conditions and malig-
nancies, as well as in the availability of
potentially dangerous treatments, the
number of immunosuppressed patients
exposed to the risk of severe or fatal
complications of an unrecognized, chronic
S. stercoralis infection is likely to grow at a
fast rate. More generally, the impact of
this parasite on the total morbidity and
mortality in the low-middle income coun-
tries is poorly known. In a recent study in
Coˆte d’Ivoire comparing self-reported
morbidity of S. stercoralis versus hookworm,
a trend toward worse health conditions,
particularly in those infected with S.
stercoralis, was observed. Moreover, the
perceived health impact of strongyloidiasis
was greater than that of hookworm,
mainly concerning abdominal and respi-
ratory symptoms and skin problems [14].
A further concern is that, while the
prevalence of the other soil-transmitted
helminths (STH) is declining, mass treat-
ment campaigns are unlikely to impact on
S. stercoralis, except in countries where
ivermectin, the drug of choice for stron-
gyloidiasis, has been introduced for con-
trol/elimination of onchocerciasis and
lymphatic filariasis [22,23].
Therapy remains an area of partial
uncertainty, too, as the optimal dosage
schedule of ivermectin has yet to be
Figure 1. Embryonated eggs of Strongyloides stercoralis in bronchial fluid from a fatal case of disseminated strongyloidiasis (photo
by Maria Gobbo, CTD Negrar, Verona).
doi:10.1371/journal.pntd.0002214.g001
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defined [24,25]. Solely reducing the worm
burden, which may be an acceptable goal
for other helminths, is not enough in this
case, as this worm is capable of replicating
itself in the host due to its peculiar
autoinfection cycle. Moreover and for the
same reason, this infection can last lifelong
even in the absence of a reinfection, if not
adequately treated [19]. A number of
randomized clinical trials have been car-
ried out, showing that ivermectin is the
drug of choice, and a single dose is highly
effective (over 90% in most studies)
[26,27]. However, drug efficacy may have
been overestimated, as faecal-based meth-
ods alone have been used to assess cure in
almost all studies. Multiple doses may be
necessary to obtain the goal of eradication
in a patient, and the current indications by
WHO refer to a schedule of two consec-
utive days as a possible alternative to the
single dose [28]. However, a single dose
may be appropriate for mass treatment, as
even the clinical trial with the most strict
criteria of cure (combining serology with
feacal-based diagnostic methods) docu-
mented eradication of the infection in
almost 70% of patients [24]. Currently,
ivermectin is being used for mass treat-
ment of filariasis: estimating the impact on
strongyloidiasis in countries where this
drug has been used in mass treatment
would be useful for planning control
actions. A recent study in Zanzibar
showed a dramatic impact on STH
prevalence following mass treatment with
ivermectin plus albendazole for control of
lymphatic filariasis; moreover, a tremen-
dous reduction was observed in the
incidence of scabies, too, which is known
to respond well to ivermectin [29]. Further
studies comparing areas where NTD
control strategies include filariasis with
areas where ivermectin has not been used,
together with a more reliable mapping of
S. stercoralis prevalence, would be crucial to
guide focused actions for the control of this
parasite.
In summary, many gaps in knowledge
remain and should be addressed by future
research. Networking is crucial among the
relatively few researchers interested in this
neglected infection to improve coordina-
tion and optimize resources. An informa-
tion sharing point has been recently
opened on the WHO website for this
purpose. Meanwhile, we already know a
great deal. We know that this parasite kills;
we know that the infection can last lifelong
in the absence of effective treatment; we
know that the prevalence is probably
much higher than previously estimated;
we know that current regimens for mass
treatment of STH are not adequate unless
they include ivermectin; we know that the
latter is the drug of choice for strongyloi-
diasis; and we have substantial experience
in the large-scale use of this drug.
Despite many remaining grey areas, the
existing evidence calls for the following
urgent, essential steps to be taken:
– Prevalence studies of STH should also
target S. stercoralis using adequate
diagnostic tools, and include compara-
tive studies in areas where ivermectin
has long been used for onchocerciasis
and lymphatic filariasis control/elimi-
nation. This should ideally include
development of new diagnostics for
use in field settings.
– Donors and funding agencies interest-
ed in supporting NTD research and
control should not ignore S. stercoralis,
currently a Cinderella in this arena.
– A forum of experts should establish
prevalence thresholds with the current-
ly available diagnostic tools in order to
define S. stercoralis as a public health
problem, and propose control strate-
gies including mass treatment regi-
mens.
– Ivermectin should be made available
for mass treatment in countries/areas
with high prevalence.
– Adequate screening and treatment
strategies should be the rule for patients
at risk of immunosuppression, both in
low-middle and high income countries.
More sensitive tests for parasitological
cure are required.
We know enough to call for action now.
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